je.st
news
Tag: cancers
New Studies Investigating the Use of KEYTRUDA (pembrolizumab) Across Solid and Hematological Cancers to Be Presented at Upcoming Congresses
2015-11-17 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. First-Time Presentation of KEYTRUDA Compared to Chemotherapy in Advanced Non-Small Cell Lung Cancer From KEYNOTE-010 Study New Findings of KEYTRUDA in Novel Combinations with Other Immunotherapies in Advanced Melanoma First-Time Findings in Multiple Myeloma and ER-Positive/HER2-Negative Breast Cancer as Well as New Findings in Classical Hodgkin Lymphoma KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that data investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in advanced non-small cell lung cancer, melanoma, classical Hodgkin lymphoma, multiple myeloma, and ER-positive/HER2-negative breast cancer will be presented at four medical congresses through the end of this year. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: to
presented
studies
solid
Data in Nine Difficult-to-Treat Cancers from Mercks KEYTRUDA (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: ...
2015-09-21 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. ...Nasopharyngeal Carcinoma, Anal Cancer, Merkel Cell Carcinoma and Biliary Tract Cancer Data to Include First-Time Findings on the Potential Importance of PD-L2 Expression in Predicting Patient Responsiveness to Anti-PD-1 Therapy KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new data investigating the anti-tumor activity of KEYTRUDA (pembrolizumab) across a broad range of advanced cancers will be presented at this years European Cancer Congress (ECC) in Vienna, Austria, Sept. 25-29. In total, 15 KEYTRUDA-related abstracts across nine difficult-to-treat cancers will be presented at this years ECC including four late-breaking oral presentations. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
New Pig Model to Provides Insights into Cancers
2015-08-07 02:00:00| ThePigSite - Industry News
US - For the last several years, researchers at the University of Illinois have studied gene expression in mice, humans, and pigs in an effort to create a large-animal model that is more relevant to human cancers.
Tags: model
insights
pig
cancers
International Scientific Forum on Alcohol Research Critique 165: Fibre Intake may Modify the Association of Alcohol Consumption with Certain Hormone-Dependent Cancers
2015-06-04 14:04:54| Daily beverage news and comment - from just-drinks.com
The positive association between alcohol intake and certain hormone-dependent cancers - especially breast cancer- that has been noted in many studies has been attributed to an effect of alcohol through an increase in levels of estrogen and other hormones.
Tags: with
forum
international
research
2015 ASCO Annual Meeting: New Data in 10 Different Cancers from Mercks Rapidly Expanding Immuno-Oncology Research Program for KEYTRUDA (pembrolizumab) to be Presented
2015-05-13 23:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. New Findings Show Anti-tumor Activity of KEYTRUDA in Five Additional Cancers: Colorectal, Esophageal, Ovarian, Renal Cell Carcinoma and Small-Cell Lung Cancer First-Time Presentations of DNA Mismatch Repair Deficiency Data in Colorectal and other Cancers and Nanostring RNA Data in Melanoma, Head and Neck and Gastric Cancers Industry-leading Number of PD-1 Clinical Trials Resulting in Growing Body of Data for KEYTRUDA across 13 Tumor Types KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new investigational data in 10 different types of cancer from the companys immuno-oncology development program evaluating its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 29 June 2, 2015. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: to
data
research
program